These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 29040714)

  • 1. NICE issues positive recommendation for XELJANZ®▼(tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis.
    Rheumatology (Oxford); 2017 Dec; 56(12):e49. PubMed ID: 29040714
    [No Abstract]   [Full Text] [Related]  

  • 2. Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma.
    Younis US; Vallorz E; Addison KJ; Ledford JG; Myrdal PB
    AAPS PharmSciTech; 2019 Apr; 20(5):167. PubMed ID: 30993508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study".
    Thai TN; Dawwas GK
    Arthritis Res Ther; 2018 Aug; 20(1):198. PubMed ID: 30157957
    [No Abstract]   [Full Text] [Related]  

  • 4. Tofacitinib in the treatment of active rheumatoid arthritis in adults.
    Fleischmann R
    Immunotherapy; 2018 Jan; 10(1):39-56. PubMed ID: 29043892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib: A Review in Rheumatoid Arthritis.
    Dhillon S
    Drugs; 2017 Dec; 77(18):1987-2001. PubMed ID: 29139090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.
    Mori S; Yoshitama T; Ueki Y
    Intern Med; 2018 Mar; 57(5):663-670. PubMed ID: 29151519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.
    Winthrop KL; Korman N; Abramovits W; Rottinghaus ST; Tan H; Gardner A; Mukwaya G; Kaur M; Valdez H
    J Am Acad Dermatol; 2018 Jun; 78(6):1149-1155.e1. PubMed ID: 29080806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and functional actions of tofacitinib related to the pathophysiology of hibernoma development.
    Radi ZA; Vogel WM; Bartholomew PM; Koza-Taylor P; Papanikolaou A; Wisialowski T; Nambiar P; Ball DJ
    Regul Toxicol Pharmacol; 2017 Dec; 91():93-102. PubMed ID: 29074274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.
    Kawalec P; Śladowska K; Malinowska-Lipień I; Brzostek T; Kózka M
    Ther Clin Risk Manag; 2018; 14():15-29. PubMed ID: 29317823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation and cluster analysis of immunomodulatory drugs based on cytokine profiles.
    Wallner FK; Hultquist Hopkins M; Woodworth N; Lindvall Bark T; Olofsson P; Tilevik A
    Pharmacol Res; 2018 Feb; 128():244-251. PubMed ID: 29079427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of sarilumab for the treatment of rheumatoid arthritis.
    Lee EB
    Immunotherapy; 2018 Jan; 10(1):57-65. PubMed ID: 29043871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating Early Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Direct and Indirect Trial Evidence.
    Lopez-Olivo MA; Kakpovbia-Eshareturi V; des Bordes JK; Barbo A; Christensen R; Suarez-Almazor ME
    Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1355-1365. PubMed ID: 29161466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis.
    Nagaraj S; Barnabe C; Schieir O; Pope J; Bartlett SJ; Boire G; Keystone E; Tin D; Haraoui B; Thorne JC; Bykerk VP; Hitchon C;
    Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1245-1250. PubMed ID: 29125904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme.
    Yamanaka H; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Novelli Horne L; Inoue E; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SMM; Wesby-van Swaay E; Nyberg F
    RMD Open; 2017; 3(2):e000498. PubMed ID: 29081988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.
    Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J
    Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
    Vainchenker W; Leroy E; Gilles L; Marty C; Plo I; Constantinescu SN
    F1000Res; 2018; 7():82. PubMed ID: 29399328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.